CINCinactive

CinCor Pharma, Inc.

Healthcare·Cardiovascular·Phase 2
CardiovascularNephrology

CinCor Pharma, Inc. (CINC): 2 pipeline candidates · ~72 mo cash runway. Updated within the last hour.

7.7/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway10.0

72.1 months

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for CinCor Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$292.6M

Quarterly Burn

$15.1M

Runway

72.1 mo

Revenue

—

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jun 2032
Today~79 mo out
Catalyst within runway

Pipeline (2 candidates)

DrugPhase
baxdrostat—
cin-107Phase 2

Frequently asked questions

How many drug candidates are in CinCor Pharma, Inc.'s pipeline?

CinCor Pharma, Inc. (CINC) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is CinCor Pharma, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CinCor Pharma, Inc. has approximately 72.1 months of cash runway.

Get the full picture on CinCor Pharma, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar